Cencora, Inc. $COR Shares Sold by Forsta AP Fonden

Forsta AP Fonden reduced its holdings in shares of Cencora, Inc. (NYSE:COR) by 9.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 82,110 shares of the company’s stock after selling 8,760 shares during the quarter. Forsta AP Fonden’s holdings in Cencora were worth $27,733,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Norges Bank acquired a new stake in shares of Cencora in the 4th quarter valued at about $822,506,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Cencora in the 4th quarter valued at about $28,892,000. Triglav Investments D.O.O. boosted its position in shares of Cencora by 140.9% in the 4th quarter. Triglav Investments D.O.O. now owns 33,000 shares of the company’s stock valued at $11,146,000 after purchasing an additional 19,300 shares during the period. Fideuram Asset Management Ireland dac acquired a new stake in shares of Cencora in the 4th quarter valued at about $639,000. Finally, Principia Wealth Advisory LLC boosted its position in shares of Cencora by 3,462.5% in the 4th quarter. Principia Wealth Advisory LLC now owns 285 shares of the company’s stock valued at $96,000 after purchasing an additional 277 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Up 0.6%

COR opened at $269.21 on Friday. The business has a 50 day moving average price of $298.56 and a two-hundred day moving average price of $333.91. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The company has a market cap of $52.38 billion, a PE ratio of 20.65, a P/E/G ratio of 1.23 and a beta of 0.64. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the company earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, research analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s dividend payout ratio is currently 18.40%.

Cencora announced that its board has approved a stock buyback plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on COR. Barclays upped their target price on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research report on Friday, February 13th. Robert W. Baird decreased their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Wells Fargo & Company decreased their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Weiss Ratings cut Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 22nd. Finally, Evercore set a $360.00 target price on Cencora in a research report on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.